Provided by Tiger Trade Technology Pte. Ltd.

Acumen Pharmaceuticals, Inc.

2.40
+0.15006.67%
Post-market: 2.430.0300+1.25%19:48 EST
Volume:504.81K
Turnover:1.21M
Market Cap:145.38M
PE:-1.09
High:2.47
Open:2.30
Low:2.27
Close:2.25
52wk High:3.05
52wk Low:0.8551
Shares:60.57M
Float Shares:32.93M
Volume Ratio:0.92
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2064
EPS(LYR):-1.7051
ROE:-85.93%
ROA:-42.23%
PB:1.56
PE(LYR):-1.41

Loading ...

Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS)

TIPRANKS
·
Feb 03

Acumen Pharmaceuticals Chief Legal Officer Derek Meisner Reports Disposal of Common Shares

Reuters
·
Jan 29

Analysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS) and InMode (INMD)

TIPRANKS
·
Jan 27

Acumen Pharmaceuticals Is Maintained at Buy by BTIG

Dow Jones
·
Jan 27

U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings

Reuters
·
Jan 27

January 2026's Rising Stars: Top Penny Stocks To Watch

Simply Wall St.
·
Jan 20

Acumen Pharmaceuticals Chief Legal Officer Derek Meisner Reports Sale of Common Shares

Reuters
·
Jan 13

BRIEF-Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology For Oligomer-Selective Antibodies

Reuters
·
Dec 02, 2025

Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer’s Antibody in Phase 2 Trial

Reuters
·
Dec 02, 2025

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 Altitude-Ad Clinical Trial at 18TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference

THOMSON REUTERS
·
Dec 02, 2025

Acumen Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Nov 19, 2025

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

GlobeNewswire
·
Nov 18, 2025

Acumen Pharmaceuticals Doses First Participant in Phase 2 Extension Study of Sabirnetug for Early Alzheimer’s Disease

Reuters
·
Nov 17, 2025

Acumen Pharmaceuticals Inc: Acumen Expects to Report Topline Results From Altitude-Ad in Late 2026

THOMSON REUTERS
·
Nov 17, 2025

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People With Early Alzheimer’s Disease

THOMSON REUTERS
·
Nov 17, 2025

Acumen Pharmaceuticals Inc - May Offer Common Stock up to $50 Mln - SEC Filing

THOMSON REUTERS
·
Nov 13, 2025

Citi Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS)

TIPRANKS
·
Nov 13, 2025

Acumen Pharmaceuticals’ Earnings Call: Progress and Challenges

TIPRANKS
·
Nov 13, 2025

Acumen Pharmaceuticals Unveils Sabirnetug Data Targeting Early Alzheimer’s Disease

Reuters
·
Nov 12, 2025

Acumen Pharmaceuticals Reports Q3 Financial Results

TIPRANKS
·
Nov 12, 2025